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Approche et objectif 
L'objectif de la recherche était de préciser les relations existant entre l'insuffisance rénale chronique, 
l'anémie et l'accident vasculaire cérébral parmi des patients hospitalisés au Centre Hospitalier 
Universitaire Vaudois (CHUV) pour un accident vasculaire cérébral (A VC). Les auteurs ont déterminé 
la prévalence de l'anémie et de l'insuffisance rénale chronique parmi ces patients et examiné s'ils sont 
des facteurs de risque indépendants de la mortalité suite à un AVC. 
L'insuffisance rénale chronique est associée à un risque élevé de développer un AVC. L'anémie est 
une complication et une conséquence fréquente qui découle de l'insuffisance rénale chronique et est 
également un facteur de risque pour les maladies cérébro- et cardiovasculaires. 
Méthode 
La présente étude de cohorte rétrospective se base sur le registre des AVC du CHUV et inclut tous les 
patients traités suite à un premier A VC au service de neurologie du CHUV entre les années 2000 et 
2003. 
Les variables utilisées pour l'analyse sont les caractéristiques démographiques, l'insuffisance rénale 
chronique, le débit de filtration glomérulaire (GFR), l'anémie et d'autres facteurs de risque d' AVC. Ils 
ont été récoltés au moyen du système informatique du laboratoire du CHUV, d'entretiens 
téléphoniques (patients ou proches) et du registre des AVC du CHUV. 
L'insuffisance rénale chronique a été calculée sur base de la ,,Kidney Disease Outcomes Quality 
Initiative (K/DOQI)-CKD Classification'', laquelle est divisée en cinq stades. L'anémie a été définie 
par une hémoglobine de< 120g/L pour les femmes et< 130g/L pour les hommes. 
Les analyses statistiques réalisées sont des tests Chi-carré, des tests de T ainsi que des courbes de 
Kaplan-Meier et le modèle de régression de Cox. 
Résultats 
Parmi 890 patients adultes avec un AVC, le GFR moyen était de 64.3 ml/min/1.73 m2, 17% 
souffraient <l'anémie et 10% sont décédés pendant la première année après la sottie de l'hôpital, suite à 
l'"AVC index". Parmi ceux-ci, 61 % avaient une insuffisance rénale chronique de stade 3-5 et 39% de 
stade 1 ou 2 selon les critères de K/DOQI. 
D'autre part un taux d'hémoglobine élevé a pu être associé à un risque moins élevé de mortalité un an 
après la sortie de l'hôpital. 
Conclusion et perspective 
Nous avons constaté que l'anémie ainsi que l'insuffisance rénale chronique sont fréquents parmi les 
patients souffrant d'un AVC et qu'ils sont des facteurs de risque d'un taux de mortalité élevé après un 
an. En conséquence, il pourrait être utile de traiter les patients souffrant <l'anémie et d'insuffisance 
rénale dès que possible afin de diminuer les complications et comorbidités résultants de ces maladies. 
La perspective est de rendre les cliniciens attentif à l'importance de l'insuffisance rénale et de 
l'anémie parmi les patients ayants développé un AVC, ainsi que d'initier le traitement approprié afin 
de diminuer les complications, les comorbidités ainsi que les récidives d'un AVC. L'efficacité et 
l'économicité des interventions visant à améliorer le pronostic chez les patients présentant un AVC et 
souffrant d'une insuffisance rénale chronique et/ ou d'une anémie doivent être évaluées par des études 
appropriées. 
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r Abstract 
Background: Chronic kidney disease (CKD) is associated to a higher stroke risk. Anemia is a common consequence 
of CKD, and is also a possible risk factor for cerebrovascular diseases. The purpose of this study was to examine if 
anemia and CKD are independent risk factors for mortality after stroke. 
Methods: This historie cohort study was based on a stroke registry and included patients treated for a first clinical 
stroke in the stroke unit of one academic hospital over a three-year period. Mortality predictors comprised 
demographic characteristics, CKD, glomerular filtration rate (GFR), anemia and other stroke risk factors. GFR was 
estimated by means of the simplified Modification of Diet in Renal Disease formula. Renal function was assessed 
according to the Kidney Disease Outcomes Quality Initiative (K/DOQl)-CKD classification in five groups. A value of 
hemoglobin < 120 g/L in women and < 130 g/L in men on admission defined anemia. Kaplan-Meier survival 
curves and Cox models were used to describe and analyze one-year survival. 
Results: Among 890 adult stroke patients, the mean (Standard Deviation) calculated GFR was 64.3 (17.8) ml/min/ 
1.73 m2 and 17% had anemia. Eighty-two (10%) patients died during the first year after discharge. Among those, 
50 (61%) had K/DOQI CKD stages 3 ta 5 and 32 (39%) stages 1 or 2 (p < 0.001). Anemia was associated with an 
increased risk of death one year after discharge (p < 0.001 ). After adjustment for other factors, a higher 
hemoglobin level was independently associated with decreased mortality one year after discharge [hazard ratio 
(95% Cl) 0.98 (0.97-1.00)]. 
Conclusions: Bath CKD and anemia are frequent among stroke patients and are potential risk factors for 
decreased one-year survival. The inclusion of patients with a first-ever clinical stroke only and the determination of 
anemia based on one single measure, on admission, constitute limitations to the external validity. We should 
investigate if an early detection and management of bath CKD and anemia could improve survival in stroke 
patients. 
Introduction 
Stroke is an increasing cause of mortality and severe 
neurological disability, including late-life dementia, 
worldwide [1-3]. Chronic kidney disease (CKD) is an 
independent risk factor for cerebrovascular diseases 
[ 4,5]. Anemia, a frequent feature of reduced kidney 
fonction, could actually play a role in the relationship 
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between CKD and stroke [6]. However, the relationship 
between CKD-, anemia- and stroke-related outcomes 
needs to be studied further. Chronic kidney disease 
(CKD) is also an increasing public health problem 
worldwide, associated with poor outcomes and high cost 
[7]. A loss of renal fonction is associated with an ele-
vated risk of stroke and cardiovascular diseases com-
pared to the general population [8-10]. Other risk 
factors for stroke are commonly encountered in dialysis 
patients [11]. 
© 2010 Del Fabbro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
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Friedman found out that serum creatinine is a strong 
and independent predictor of survival after a stroke [12], 
while another study indicated that this association was 
related to the presence of anemia [ 6]. When anemia was 
present with chronic kidney disease, the risk of stroke 
increased clearly compared to patients with CKD with-
out anemia, in which the risk of stroke was only moder-
ately increased. Among those patients with anemia and 
low creatinine clearance the crude stroke rate per 1000 
person-years was 10.53 and, among those without ane-
mia and low creatinine clearance, the rate was 2.85 [6]. 
To further study the role of CKD and anemia on out-
come in stroke patients, the objective of this study was 
to examine the association between chronic kidney dis- . 
ease and anemia with in-hospital mortality and one-year 
survival among hospitalized stroke patients. 
Patients and Methods 
Setting, patients 
In this retrospective cohort study, all consecutive 
patients hospitalized with a diagnosis of a first ever clin-
ical stroke, and recorded in the Stroke Registry of the 
Neurology Service of an academic medical center in 
Western Switzerland, were included [13]. AU patients 
discharged from the hospital after a hemorrhagic or 
ischemic stroke between 1 st January 2001 and 31 st 
December 2003 were considered for inclusion in a retro-
spective cohort study. We excluded patients who could 
not be reached at follow-up, especially those living 
abroad, refusais and cases with missing values for creati-
nine or hemoglobin, as well as subjects with incomplete 
coded discharge information. 
Data collection 
Unless otherwise indicated, all information was retrieved 
from the Hospital Stroke Registry. This Stroke Registry 
was limited to patients with a first ever clinical stroke 
admitted to the Centre Hospitalier Universitaire Vaudois 
since 1979 [13]. With the exception of one-year survival, 
all information was collected during the index hospitali-
za tion for a first ever clinical stroke. Information on 
demographic characteristics and risk factors for stroke. 
(i.e. hypertension, hypercholesterolemia, diabetes, and 
smoking habits (ex-, current or non-smoker)) were col-
lected from the Stroke Registry. Other variables included. 
the presence of ischemic heart disease and atrial fibrilla-
tion, peripheral arterial insufficiency (defined according 
to the clinical definition of claudication classified by 
Fontaine), a positive family history for stroke and/or 
heart disease and transient ischemic attack (TIA: a neu-
rological disorder due to a temporary ischemia of the 
brain which lasts less than 24 hours). This information 
was prospectively asked to the patients or their family 
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members at admission to the hospital and added to the 
stroke registry. Diabetes was considered present if fast-
ing plasma glucose was >7.0 mmol/l, a 2-hour value in 
the oral glucose tolerance test or a random plasma glu-
cose concentration >11.1 mmol/l, in the presence of 
symptoms [14]. Dyslipidemia was retained if LDL was 
>2.6 mmol/l, or if, in absence of a LDL value, total cho-
lesterol was >5 mmol/l [15]. Patients with already trea-
ted diabetes and hypercholesterolemia were also 
registered. The presence of Ischemic heart disease was 
categorized as follows: none; Ischemic Heart disease 
(regrouping angina without heart attack and heart 
attack), and heart failure. 
An evaluation of the functional status was also col-
lected from the Registry. The functional status is a dis-
ability scale that represents the activities of daily living in 
a five-level scale with Stage I representing no disability, 
Stage II mild disability (return to all activities, although 
with difficulty), Stage III moderate disability (return to 
main activities, although with difficulty), Stage IV severe 
disability (impossible to return to most activities) and 
Stage V de a th. W e did not use the widely used modified 
Rankin Scale (mRS) because our five-level scale was used 
since the creation of the Lausanne Stroke Registry (LSR) 
in 1978. At this time, the mRS had not yet been defined. 
In comparison, Stage I (LSR) corresponds to Stage 0-I 
(mRS), Stage II to Stage Il, Stage III to Stage III-IV, Stage 
IV to Stage V and Stage V to Stage VI. The serum creati-
nine, hemoglobin and hematocrit values were collected 
from the electronic files of the hospital's laboratory. The 
first hemoglobin and serum creatinine values of the hos-
pitalization were used for each patient. Anemia was 
defined as a hemoglobin level <120 g/L in women and 
<130 g/L men according to the World Health Organiza-
tion (WHO) definition [16]. We estimated the Glomeru-
lar Filtration Rate (GFR) by means of the simplified 
Modification of Diet in Renal Disease formula [17,18]. 
Renal function was assessed according to the Kidney Dis-
ease Outcomes Quality Initiative (K/DOQI)-CKD classifi-
cation in five groups [17]. Stage I corresponded to 
patients with GFR values ;:::90 ml/min/1.73 m2, Stage II to 
GFR values from 60 to 89 ml/min/1.73 m2 , Stage Ill 
to GFR values from 30 to 59 ml/min/1.73 m2, Stage IV to 
GFR values from 15 to 29 ml/min/1.73 m2, and Stage V 
to GFR values <15 ml/min/1.73 m2 • The Stroke Registry 
number allowed us to access to the medical chart for 
each stroke patient hospitalized between 2001 and 2003, 
featuring all necessary information about the patients, 
such as interventions, reports of admission notes and 
medical consultations and discharge letters, discharge 
status including death, and discharge diagnoses (Interna-
tional Classification of Diseases 10th Revision (ICD-10)). 
The Charlson comorbidity index, a weighted average of 
Del Fabbro et al. BMC Nephrology 2010, 11 :27 
http://www.biomedcentral.com/1471-2369/11 /27 
selected comorbidities, was calculated by means of 
administrative data, using an algorithm that was recently 
developed for ICD-10 codes [19]. 
Main outcome measures 
The outcomes of interest were in-hospital mortality and 
one-year survival in .hospitalized stroke patients. Follow-
up information to establish survival after discharge from 
hospital was collected via telephone interviews with the 
patients, their relatives, their physicians, and/or the nur-
sing homes. For a few patients, this information was 
obtained from Population Registries. The one-year mor-
tality rate was calculated from the date of discharge 
from hospital. 
Statistical analyses 
Bivariate analyses, including chi-square tests, Fisher's 
exact tests, Student T-tests or ANOV A methods, where 
appropriate, were used in a first step. Kaplan-Meier 
(KM) survival curves were obtained using the log rank 
test to assess if KM survival curves for patients with or 
without CKD or with different levels of hemoglobin 
were statistically different. For these survival curves, the 
follow-up was extended up to over five years, to a maxi-
mum of 1889 days. A univariate survival analysis was 
performed, using hemoglobin and GFR as continuous 
variables (Cox proportional hazard analysis). 
We then conducted multivariate analyses adjusted for 
potential confounding factors. Cox models were used to 
assess one-year survival and to calculate adjusted hazard 
ratios with their associated 95% confidence intervals [20]. 
W e checked the proportional hazard assumption. Our 
modeling strategy was based on a priori consideration of 
bivariate analyses' results and clinical judgment to select 
the more important variables. W e applied the Mickey 
and Greenland method to select the final mode!, using a 
step-forward regression method with a p-value for entry 
of 0.20 [21]. Variables included in the first mode! were 
hemoglobin, GFR, age, gender, hypertension, diabetes, 
past and current smokers (reference = non smokers), 
hypercholesterolemia, heart failure, ischemic heart dis-
ease, peripheral arterial insufficiency, atrial fibrillation, 
TIA before the stroke attack, functional status in four 
categories (reference = functional status I), and the Charl-
son comorbidity index in four categories (reference = 
Charlson score 0 or 1). A significance level of 0.05 was 
used in all statistical analyses clone in this study. All ana-
lyses were performed with the SAS Software, version 9.1 
(SAS Institute, Cary, NC, USA). 
The collection and use of the data was authorised by 
the Federal Data Protection and Information Commis-
sioner within the framework of the Data Protection 
Law. Every included patient gave informed consent. 
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Results 
Baseline Characteristics 
A total of 963 eligible patients aged 16 to 97 were consid-
ered. We excluded two patients who had a transient 
ischemic attack and not a stroke, and three patients who 
had already had a previous symptomatic stroke. In addi-
tion, 10 subjects who could not be reached by phone, five 
who denied participation and 20 patients living abroad 
were excluded, as well as 16 with missing laboratory 
values for creatinine or hemoglobin, 10 discharged in 
2004, and seven because of missing ICD-10 diagnostic 
codes. Among the 890 patients included, the mean (stan-
dard deviation: SD) age was 69.0 (15.7) years (25th to 75th 
interquartile range 59-80); 54% were men. A history of 
hypertension was present in 59% of patients, 15% had 
diabetes, 39% hypercholesterolemia, and 22% were cur-
rent smokers. A history of cardiovascular disease was 
reported by 41% of the patients, a family history of stroke 
or coronary artery disease by 2%, migraine by 2%, TIA 
before stroke by 9%, and peripheral arterial insufficiency 
by 4% (Table 1, columris 1 and 2). The mean (SD) Charl-
son comorbidity index was 2.8 (1.6). 
Prevalence of CKD 
The mean (SD) serum creatinine value was 102.7 (43.3) 
µmol/L (25th to 75th interquartile range: 83 to 109 
µmol/L). The mean (SD) calculated GFR was 64.3 (17.8) 
ml/min/1.73 m2 (25th to 75th interquartile range: 53.7 to 
76.2 ml/min/1.73 m2). The distribution of renal impair-
ment according to K/DOQI CKD stages among the 
entire cohort showed that 59 (7%), 469 (53%), 335 
(38%), 21 (2%) and 6 (1%) of the patients had Stages I 
to V GFR respectively. The mean GFR was statistically 
lower in elderly patients, in women, in patients with 
hypertension, diabetes, a history of heart diseases, heart 
failure, and a family history for stroke (Table 2). 
Prevalence of Anemia 
The mean (SD) hemoglobin at admission was 139 (18) g/L 
(251h to 75th interquartile range 129-152 g/L). Hemoglobin 
<140 g/L was found in 53% of the patients, 35% had 
hemoglobin between 120 g/L and 140 g/L and 12% <120 
g/L. Anemia was present in 148 patients (17%). Figure 1 
depicts the frequencies of stroke patients by categories of 
hemoglobin, according to K/DOQI CKD stages. Among 
patients with hemoglobin <120 g/L, a lower proportion of 
K/DOQI CKD Stages I or II was observed compared to 
patients with hemoglobin >140 g/L (Table 3). The mean 
GFR was progressively lower with an increasing severity of 
anemia (Table 3) across the three hemoglobin categories. 
Anemia was present in 67 patients (45%) with K/DOQI 
CKD Stages I or II and 81 (55%) with K/DOQI CKD 
Stages III to V (p < 0.0001). 
Del Fabbro et al. BMC Nephro/ogy 201 O, 11 :27 
http://www.biomedcentral.com/1471-2369/11/27 
Page 4 of 10 
Table 1 Hospital and One-Year Mortality Related to Patients Characteristics and Risk Factors for Stroke, CHUV, 2001-
2003, N = 890 on admission and N = 857 at one year 
Characteristic and risk factors for stroke 
N (%) 
Age 
<60 years 
60-70 years 
71-80 years 
<80 years 
Gender 
Male 
Female 
Risk Factors for Stroke 
Hypertension 
Diabetes 
Hypercholesterolemia 
Smoking 
No 
Yes 
Ex-smoker 
Antecedent 
lschemic Heart Disease 
Heart failure 
Peripheral Arterial lnsufficiency 
Atrial Fibrillation 
Positive Family History for Stroke/Heart Disease 
TIA Before Stroke 
Severity of disease 
Functional Status 
1 
Ill 
IV 
Death 
Charlson Comorbidty Index 
Charlson score O or 1 
Charlson score 2 
Charlson score 3 
Charlson score 24 
Chronic Kidney Disease 
Stage 1 (GFR 290) 
Stage 2 (GFR: 60-89) 
Stage 3 (GFR: 30-59) 
Stage 4 or 5 (GFR s29) 
Mean (SD) GFR ml/min/1.73 m 2 
TIA: Transient lschemic Attack. 
GFR: Glomerular Filtration Rate ml/min/1.73 m2• 
Number (%) 
N (%) 
240 (27.0) 
151 (17.0) 
267 (30.0) 
232 (26.0) 
479 (53.8) 
411 (46.2) 
528 (59.3) 
133 (15.0) 
346 (38.9) 
595 (66.8) 
198 (22.2) 
97 (11.0) 
126 (14.2) 
97 (11.0) 
36 (4.0) 
125 (14.0) 
16 (1.8) 
77 (8.7) 
263 (29.6) 
201 (22.6) 
164 (18.4) 
230 (25.8) 
32 (3.6) 
268 (30.1) 
93 (10.5) 
298 (33.5) 
231 (26.0) 
59 (6.3) 
469 (52.7) 
335 (37.6) 
27 (3.0) 
64.3 (17.8) 
Hospital 
mortality 
N (%) 
33 (3.7) 
2 (6.1) 
1 (3.0) 
11 (33.3) 
19 (57.6) 
14 (42.4) 
19 (57.6) 
19 (57.6) 
3 (9.1) 
6 (18.2) 
30 (90.9) 
3 (9.1) 
0 
7 (21.2) 
8 (24.2) 
0 
9 (27.3) 
0 
2 (6.1) 
0 
0 
0 
1 (3.0) 
32 (97.0) 
7 (21.2) 
3 (9.1) 
12 (36.4) 
11 (33.3) 
0 
13 (39.4) 
18 (54.6) 
2 (6.1) 
55.2 (12.6) 
P'value 
<0.001 
0.21 
0.86 
0.46 
0.02 
0.009 
0.30 
0.02 
0.64 
0.04 
1.00 
1.00 
<0.001 
0.62 
0.052 
<0.001 
One-Year 
mortality 
N (%) 
82 (9.6) 
6 (7.3) 
6 (7.3) 
26 (31.7) 
44 (53.7) 
39 (47.6) 
43 (52.4) 
49 (59.8) 
17 (20.7) 
19 (23.2) 
67 (81.7) 
6 (7.3) 
9 (11.0) 
15 (18.3) 
20 (24.4) 
9 (11.0) 
16 (19.S) 
0 
2 (2.4) 
6 (7.3) 
10 (8.2) 
13 (15.9) 
53 (64.6) 
11 (13.4) 
9 (11.0) 
24 (29.3) 
38 (46.3) 
5 (6.1) 
27 (32.9) 
43 (52.4) 
7 (8.5) 
55.6 (20.6) 
P value 
<0.001 
0.20 
1.00 
0.15 
0.001 
0.002 
0.24 
<0.001 
0.005 
0.12 
0.34 
0.04 
<0.001 
<0.001 
<0.001 
<0.001 
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Table 2 Chronic Kidney Disease Prevalence and Mean Glomerular Filtration Rate according to Patients Characteristics 
and Risk Factors for Stroke, CHUV, 2001-2003, N = 890 
Characteristic and risk factors for stroke Number 
N (%) 
Chronic Kidney Disease 
N (%) 
P value Mean (SD) P value 
GFR 
N (%) 
Age 
s60 years 
60-70 years 
71-80 years 
<80 years 
Gender 
Male 
Female 
Risk Factors for stroke 
Hypertension 
Diabetes 
Hyper-Cholesterolemia 
Smoking 
No 
Yes 
Ex-smoker 
Antecedent 
lschemic Heart Disease 
Heart failure 
Peripheral Arterial lnsufficiency 
Atrial Fibrillation 
Positive Family History for Stroke/ 
Heart Disease 
TIA before Stroke 
Severity of disease 
Functional Status 
Ill 
IV 
Death 
Charlson score 
Charlson score 0 or 1 
Charlson score 2 
Charlson score 3 
Charlson score 24 
TIA: Transient lschemic Attack. 
GFR: Glomerular Filtration Rate ml/min/1.73 m2• 
Survival 
1 
890 (100.0) 59 (6.6) 
240 (27.0) 
151 (17.0) 
39 (16.3) 
10 (6.6) 
267 (30.0) 8 (3.0) 
232 (26.0) 2 (0.86) 
479 (53.8) 52 (10.9) 
411 (46.2) 7 (1.7) 
528 (59.3) 
133 (15.0) 
346 (38.9) 
595 (66.8) 
198 (22.2) 
97 (11.0) 
126 (14.2) 
97 (11.0) 
36 (4.0) 
125 (14.0) 
16 (1.8) 
77 (8.7) 
22 (4.2) 
11 (8.3) 
20 (5.8) 
24 (4.03) 
30 (15.15) 
5 (5.15) 
3 (2.4) 
3 (3.1) 
2 (5.6) 
4 (3.2) 
4 (25) 
5 (6.5) 
263 (29.6) 11(4.2) 
201 (22.6) 20 (9.9) 
164 (18.4) 10 (6.1) 
230 (25.8) 18 (7.8) 
32 (3.6) 0 
268 (30.1) 18 (6.7) 
93 (10.5) 2 (2.2) 
298 (33.S) 23 (7.7) 
231 (26.0) 16 (6.9) 
Thirty-three (3.7%) patients <lied during their hospitali-
zation. Among them, 20 (61 %) had K/DOQI CKD 
Stages III to V and 13 (39%) Stages I or II (p = 0.052), 
and their mean GFR was 55.2 ml/min/1.73 m2• Eighty-
two (10%) patients <lied during the first year of follow-
up. Among them 50 (61%) had K/DOQI CKD Stages III 
to V and 32 (39%) Stages I or II (p < 0.0001), and their 
Il 111 
469 (52.7) 335 (37.6) 
177 (73.8) 20 (8.3) 
92 (60.9) 47 (31.1) 
121 (45.3) 127 (47.6) 
79 (34) 141 (61) 
287 (59.9) 126 (26.3) 
182 (44.3) 209 (50.9) 
IV-V 
27 (3.0) 
4 (1.7) 
2 (1.3) 
11 (4.1) 
10 (4.3) 
14 (2.9) 
13 (3.2) 
246 (46.6) 239 (45.3) 21 (3.9) 
51 (38.3) 64 (48.1) 7 (5.3) 
181 (52.3) 135 (39) 10 (2.9) 
285 (48) 268 (45.04) 18 (3.03) 
127 (64.1) 37 (18.7) 
57 (58.8) 30 (31) 
55 (43.7) 62 (49.2) 
35 (36. l) 54 (55.7) 
18 (50) 14 (38.9) 
51 (40.8) 64 (51.2) 
11 (68.8) 1 (6.25) 
39 (50.7) 31 (40.3) 
157 (59. 7) 92 (35) 
104 (51.7) 71 (35.3) 
91 (55.5) 54 (33) 
4 (2.02) 
5 (5.15) 
6 (4.8) 
5 (5.2) 
2 (5.6) 
6 (4.8) 
0 
2 (2.6) 
3 (1.14) 
6 (3) 
9 (5.5) 
104 (45.2) 1 OO (43.5) 8 (3.5) 
13 (40.6) 18 (56.3) 1 (3.13) 
174 (65) 74 (27.6) 2 (0.8) 
47 (50.5) 42 (45.2) 2 (2.2) 
156 (52.4) 111 (37.3) 8 (2.7) 
92 (39.8) 108 (46.8) 15 (6.5) 
<0.001 
<0.001 
<0.001 
0.003 
0.812 
<0.001 
0.005 
0.0003 
0.703 
0.0017 
0.005 
0.964 
0.006 
<0.001 
ml/min/1.73 m2 
64.3 (17.8) 
76.8 (16.5) 
67.4 (16.2) 
59.l (15.8) 
55.2 (13.9) 
69.l (18.7) 
58.6 (14.8) 
60.3 (16.9) 
59.6 (19.7) 
63.7 (17.0) 
61.1 (16.2) 
73.7 (18.ü) 
64.7 (19.8) 
59.2 (16.1) 
55.4 (17.6) 
62.4 (21.4) 
57.0 (16.8) 
79.5 (15.0) 
62.0 (17.3) 
65.3 (15.6) 
65.2 (17.8) 
65.1 (19.3) 
62.7 (19.4) 
56.2 (11.6) 
68.8 (16.2) 
62.2 (14.4) 
64.7 (17.4) 
59.2 (19.9) 
<0.001 
<0.001 
<0.001 
0.003 
0.47 
<0.001 
<0.001 
<0.001 
0.52 
<0.001 
<0.001 
0.25 
0.04 
<0.001 
mean GFR was 55.6 ml/min/1.73 m 2• Indeed, the pre-
sence of an increasing stage of CKD was associated with 
an increased risk of death during the hospitalization and 
the first year after discharge (Table 1). Anemia was also 
associated with an increased risk of death (Table 3). 
Proportions of in-hospital and one-year mortality 
increased progressively, with an increasing degree of 
anemia expressed in the three hemoglobin categories 
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Figure 1 Frequencies of Patients Hospitalised for a First Stroke, by Hemoglobin Level(< 120, 120-140, > 140 g/I), according to KI 
DOQI CKD Stage. 
(Table 3). Kaplan-Meier survival analyses indicated that 
K/DOQI CKD Stages III and IV (Figure 2) and lower 
hemoglobin (Figure 3) were risk factors for decreased 
survival, log rank test p < 0.001 and p < 0.001, 
respectively. In univariate survival analysis, both hemo-
globin and GFR were positively associated with survival, 
as indicated by hazard ratios of 0.976 (95% CI 0.966-
0.986) and 0.970 (95% CI 0.959-0.982), respectively. 
Table 3 Hemoglobin Levels Related to CKD, GFR and Mortality in Patients Hospitalized for a First Stroke, CHUV, 2001-
2003, N = 890 
Hemoglobin in g/L 
N (%) <120 g/L N (%) 120-140 g/L N (%) >140 g/L N (%) Total(%) P Value 
or Mean (SD) 
N = 890 108 (12.1) 
Gender 
Male 42 (38.9) 
Fe male 66(61.1) 
Age 
,;60 years 20 (18.5) 
60-70 years 14 (13.0) 
71-80 years 31 (28.7) 
<80 years 43 (39.8) 
Mean (SD) Hemoglobin 10.7 (12.7) 
CKD 
Stage 1 (GFR ~90) 7 (6.5) 
Stage 2 (GFR: 60-89) 40 (37.0)50 (46.3) 
Stage 3 (GFR: 30-59) 11 (10.2) 
Stage 4/5 (GFR ,;29) 
Mean (SD) GFR ml/min/1.73 m2 56.7 (21.6) 
ln-hospital mortality (N = 890) 6 (5.6) 
One-year mortality (N = 857) 23 (22.6) 
GFR: Glomerular Filtration Rate ml/min/1.73 m2• 
or Mean (SD) or Mean (SD) 
315 (35.4) 467 (52.5) 
123 (39.1) 314 (67.2) 
192 (60.1) 153 (32.8) 
60 (19.1) 160 (34.3) 
44 (14.0) 93 (19.9) 
102 (32.4) 134 (28.7) 
109 (34.6) 80 (17.1) 
13.1 (5.4) 15.2 (10.1) 
18 (5.7) 34 (7.3) 
149 (47.3) 280 (60.0) 
140 (44.4) 145 (31.1) 
8 (2.5) 8 (1.7) 
62.6 (16.8) 67.2 (16.8) 
14 (4.4) 13 (2.8) 
30 (10.0) 29 (6.4) 
890 (100) 
479 (53.8) 
411 (46.2) 
240 (27.0) 
151 (17.0) 
267 (30.0) 
232 (26.0) 
13.9 (1.8) 
59 (6.6) 
469 (52.7) 
335 (37.6) 
27 (3.0) 
64.3 (17.8) 
33 (3.7) 
82 (9.6) 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.27 
<0.001 
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Figure 2 Kaplan-Meier Survival Curve According to K/DOQI CKD Stage, among Patients Hospitalized for a First Stroke, N = 856 [GFR 
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Table 4 Results of Cox Proportional Hazard Model for One-Year Mortality in Patients Hospitalized for a First Stroke, 
CHUV, 2001-2003, N = 856 
Variables Parameter Estimate Standard Error Hazard Ratio (95% Cl) 
Hemoglobin (g/L, continuous) - 0.0163 
Glomerular filtration rate (ml/min/1.73 m 2, continuous) - 0.0114 
Age (years, continuous) 0.0398 
Hypertension - 0.3911 
Hypercholesterolemia - 0.4503 
Previous transitory ischemic attack - 1.1605 
Functional status Il (ref = 1) 0.5474 
Functional status Ill (ref = 1) 0.9331 
Functional status IV (ref = 1) 1.8335 
Charlson comorbidity index 2 (ref = O or 1) 0.4103 
Charlson comorbidity index 3 (ref = 0 or 1) 0.0646 
Charlson comorbidity index 4 (ref = O or 1) 0.6228 
*p < 0.05. 
Multivariable Analyses 
Cox models were used to assess the determinants of 
survival at one year. Hemoglobin was independently 
associated with survival at one-year (Table 4) controlling 
for age, glomerular filtration rate, hypertension, 
hypercholesterolemia, previous TIA, fonctional status 
and Charlson comorbidity index. For each 10 g/L 
increase in hemoglobin, the annual subsequent probabil-
ity of death declined by 1.6%. GFR was not .. statistically 
associated with survival in the model. The latter relation 
was not statistically significant, however. The interaction 
term between hemoglobin and GFR was also not signifi-
cantly associated with survival. 
Discussion 
We observed that anemia and chronic kidney disease are 
two frequent conditions among stroke patients. Anemia 
was independently associated with a decreased one-year 
survival. Although GFR was associated with mortality in 
bivariate analyses, this relationship was not statistically 
significant in multivariate analyses. These associations 
between reduced kidney fonction and anemia and the 
risk of death among stroke patients have not been 
reported previously. 
So far, most studies have concentrated on the risk of 
death among heart failure and myocardial infarction 
patients with CKD and anemia [22-24]. Previous studies 
already showed that CKD [25,26] and anemia [27,28] 
increase the risk of death among patients with coronary 
heart disease, heart failure and ischemic heart disease. 
In this study we wanted to assess if we observed similar 
findings for stroke patients. Previous studies have shown 
that an elevated serum creatinine concentration is asso-
ciated with an increased risk of stroke and that CKD 
and anemia are risk factors for stroke [6,29]. Indeed, 
41% of our stroke study patients were in K/DOQI CKD 
stages III to V and 17% had anemia. 
0.0056 0.98* (0.97-1.00) 
0.0073 0.99 (0.98-1.01) 
0.0113 1.04* (1.02-1.07) 
0.2359 0.68 (0.43-1.07) 
0.2728 0.64 (0.37-1.09) 
0.7230 0.31 (0.08-1.29) 
0.5196 1.73 (0.62-4.79) 
0.5008 2.54 (0.95-6.79) 
0.4471 6.26* (2.61-15.02) 
0.4564 1.51 (0.62-3.69) 
0.3743 1.07 (0.51-2.22) 
0.3662 1.86 (0.91-3.82) 
Our study findings were similar to those obtained by 
Friedman, in which serum creatinine was found to be a 
strong and independent predictor of survival after stroke 
in the elderly [12]. In our study, elevated serum creati-
nine was associated with increased hospital mortality 
and decreased one-year survival. 
Anemia is common among individuals with reduced 
kidney fonction, generally because of a decreased pro-
duction of erythropoietin [25-31]. It is a consequence of 
chronic kidney disease and it also worsens the progres-
sion of renal insufficiency. Anemia increases the preva-
lence of CKD with decreasing creatinine clearance 
[32,33]. In our study, the mean GFR was lower in 
patients with anemia and more patients in K/DOQI 
CKD Stages Ill to V had anemia. Anemia in patients 
with CKD may predispose to ischemic heart disease, 
heart failure and premature death [22,34]. Previous stu-
dies reported an increased risk of death among anemic . 
patients with or without renal impairment (35]. In our 
study, among stroke patients with anemia, the hospital 
and one-year mortality rates increased with a decreasing 
hemoglobin. 
There are different reasons why anemia and chronic 
kidney disease could be risk factors for mortality: 
chronic anemia involves hemodynamic compensations, 
for example an increase in heart rate, cardiac index and 
stroke work, as well as an amplification of hypoxia. 
These compensations stress the ventricular fonction and 
worsen the dysfonction among patients with heart fail-
ure and, thus, could consequently increase the risk of 
death [36]. Anemia is associated with changes in left 
ventricular anatomy among patients with CKD (37], a 
change that could also increase death rates. Further-
more, reduced hemoglobin may be associated with other 
risk factors of cardio-vascular mortality [29] and it may 
result in worsening ischemia by amplifying hypoxia [37]. 
Severa! studies have demonstrated that the level of 
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kidney fonction is a significant risk factor for all cause 
mortality in patients with heart failure and hypothesized 
several explanations [29]. For example, reduced kidney 
fonction may be associated with other risk factors for 
mortality. In addition, kidney disease may be a risk fac-
tor for the progression of cardiac dysfonction by wor-
sening fluid and sodium retention, thus fostering left 
ventricular dilatation and hypertrophy, a strong predic-
tor of stroke risk [38]. Furthermore CKD may induce 
other pathophysiologic processes that may increase 
stroke risk, like inducing oxidative stress, which could 
promote atherosclerosis. These elements may contribute 
to cerebral ischemia and increase the risk of ischemic 
stroke [39]. Moreover, risk factors for stroke, such as 
diabetes, hypertension or cardiovascular diseases are 
more common among dialysis patients [6] and uremia 
causes accelerated atherosclerotic vascular disease. One 
study showed that increased aortic stiffness among CKD 
patients was an explanation why CKD is a predictor of 
cardio- and cerebrovascular mortality [40,41]. 
Most patients with ESRD and even less severe kidney 
dysfonction are anemic because of a deficient erythro-
poietin production. Erythropoietin was shown to have 
neuronal protective effects in animal models of ische-
mia-induced stroke and brain injury [42]. When renal 
fonction is reduced, erythropoietin production is 
impaired, which could limit erythropoietin-induced neu-
ronal protection against anemia-induced stroke. Thus, 
the combination of anemia and CKD could interact to 
make a stroke event more likely to occur or more likely 
to be clinically severe [6]. Furthermore, it was shown 
that hemodialysis patients have better outcomes than 
patients suffering from renal insufficiency but getting no 
treatment. However, patients on continuous ambulatory 
peritoneal dialysis have a greater risk of stroke than the 
general population. This is explainable by a poor control 
of hypertension, which is presumably partly due to over-
hydration in patients getting peritoneal dialysis [43]. 
This study has several limitations. First, it included 
only patients with first-ever clinical stroke, and therefore 
did not reflect the impact of CKD and anemia on ail 
patients suffering from stroke. However, compared with 
all patients suffering from stroke, our cohort represents 
a more homogenous population, with younger patients 
in which secondary prevention and treatment may have 
higher impact. Second, we had no information on the 
duration of CKD or anemia. W e did not know the cause 
of anemia for ail patients. For some patients, anemia 
could be linked to CKD. There could be other causes of 
anemia like folate, iron, vitamin B12 deficiency, gastro-
intestinal diseases, -bleeding, cancer or chronic inflam-
matory illness. Third, we did not know the cause of 
death of the stroke patients. We did not know whether 
they <lied from complications of their stroke or from 
Page 9 of 10 
another cause. Fourth, we took all the laboratory values 
from the first day of admission to hospital. Maybe these 
values were wrongly elevated in patients who arrived in 
the hospital in a dehydrated situation. Finally, we may 
question the study's externat validity because it was con-
ducted in an academic medical centre. However, this 
centre is also the principal referral centre for the region 
from which most patients were referred. 
Conclusion 
This study has confirmed the deleterious effect of renal 
deficiency and anemia on survival in patients who sus-
tained a first stroke. We have shown that anemia is 
independently associated with a lower one-year survival. 
Thus, it might be usefol to treat patients with kidney 
disease and anemia as early as possible in order to 
reduce the complications and co-morbidities that result 
from these diseases. Indeed, CKD is very often under 
diagnosed and under-treated [12]. Appropriate trials 
should be conducted to examine if early interventions to 
detect and treat systematically renal insufficiency and 
anemia in patients experiencing a first stroke may 
improve survival and quality of life. However, the solu-
tion may not be easy. Indeed, a trial of darbepoetin alfa 
in patients with type 2 diabetes and chronic kidney dis-
ease, not undergoing dialysis, (TREAT study) has indi-
cated an increased risk of stroke [43]. 
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